MedPath

Cardiovascular Effects of a Healthy Dietary Pattern Containing Eggs

Phase 3
Recruiting
Conditions
Cardiovascular Diseases
Interventions
Registration Number
NCT06120400
Lead Sponsor
Penn State University
Brief Summary

This study will examine the effect of a healthy diet containing 2 eggs per day compared to a healthy diet containing 3 eggs per week on biomarkers of heart health after 4 weeks.

Detailed Description

This is a 2-period, randomized, crossover, controlled feeding study examining the effect of 2020-2025 Dietary Guidelines for Americans adherent dietary patterns containing 2 eggs/day/2000 kcal (HD+E) compared to 3 eggs/week/2000 kcal (HD) on biomarkers of cardiovascular health and function after 4 weeks.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
65
Inclusion Criteria
  • LDL-C ≥115 mg/dL and ≤190 mg/L
  • BMI of 25-35 kg/m2
  • Intake of <14 eggs/week for the prior 3 months
  • Blood pressure <140/90 mmHg
  • Fasting blood glucose <126 mg/dL
  • Fasting triglycerides <350 mg/dL
  • ≤10% change in body weight in the prior 6 months
Exclusion Criteria
  • Type 1 or type 2 diabetes or fasting blood glucose ≥126 mg/dL
  • Prescription of anti-hypertensive, lipid lowering or glucose lowering drugs
  • Intake of supplements that affect the outcomes of interest and unwilling to cease during the study period
  • Diagnosed liver, kidney, or autoimmune disease
  • Prior cardiovascular event (e.g., stroke, heart attack)
  • Current pregnancy or intention of pregnancy within the next 6 months
  • Lactation within prior 6 months
  • Follows a vegetarian or vegan diet
  • Food allergies/intolerance/sensitives/dislikes of foods included in the study menu
  • Antibiotic use within the prior 1 month
  • Oral steroid use within the prior 1 month
  • Use of tobacco or nicotine containing products with in the past 6 months
  • Cancer any site within the past 10 years (eligible if ≥10 years without recurrence) or non-melanoma skin cancer with in the past 5 years (eligible if ≥5 years without recurrence)
  • Participation in another clinical trial within 30 days of baseline
  • Currently following a restricted or weight loss diet
  • Prior bariatric surgery
  • Intake of >14 alcoholic drinks/week and/or lack of willingness to consume a maximum of two standard drinks per week while enrolled in the study and/or not willing to avoid alcohol consumption for 48 hour prior to test visits

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Healthy Diet (HD)Whole Egg2020-2025 Dietary Guidelines for Americans adherent dietary pattern containing 3 eggs/week/2000 kcal (HD)
Healthy Diet + Eggs (HD+E)Whole Egg2020-2025 Dietary Guidelines for Americans adherent dietary pattern containing 2 eggs/day/2000 kcal
Primary Outcome Measures
NameTimeMethod
LDL-cholesterol change4 weeks

Assessed from fasting blood draw expressed in mg/dL. LDL-cholesterol will be measured directly via enzymatic assay. Change in LDL-cholesterol will be calculated as the mean of the end of diet measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

Secondary Outcome Measures
NameTimeMethod
Change in fasting serum insulin4 weeks

Serum insulin levels assessed in a fasting blood draw and expressed in micro IU/ml

Change in fasting plasma glucose concentration4 weeks

Glucose assessed in a fasting blood draw and expressed in mg/dL

LDL-cholesterol to HDL-cholesterol ratio change4 weeks

LDL-cholesterol and HDL-cholesterol will be measured from a fasting blood draw expressed in mg/dL. The ratio will be calculated as LDL-C divided by HDL-C

Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)4 weeks

Calculated from insulin and glucose measured from a fasting blood sample. Calculated as (insulin × glucose) / 22.5

Change in carnitine4 weeks

Measured in fasting blood. Expressed as µmol/L

Triglyceride change4 weeks

Assessed from fasting blood draw expressed in mg/dL.

Change in central systolic and diastolic blood pressure4 weeks

Blood pressure measured assessed using a SphymoCor Xcel (Atcor Medical)

Change in brachial systolic and diastolic blood pressure4 weeks

Blood pressure measured assessed using a SphymoCor Xcel (Atcor Medical)

Total cholesterol change4 weeks

Assessed from fasting blood draw expressed in mg/dL.

HDL-cholesterol change4 weeks

Assessed from fasting blood draw expressed in mg/dL.

Change in particle size and number of LDL, HDL, VLDL and chylomicrons4 weeks

Measured via Nuclear Magnetic Resonance

Change in Fructosamine4 weeks

Fructosamine assess in a fasting blood draw and expressed in micro IU/ml

Change in carotid-femoral pulse wave velocity4 weeks

A measure of arterial stiffness assessed using a SphymoCor Xcel (Atcor Medical). Expressed in meters/second.

Change in trimethylamine N-oxide (TMAO)4 weeks

Measured in fasting blood. Expressed as µmol/L

Change in choline4 weeks

Measured in fasting blood. Expressed as µmol/L

Trial Locations

Locations (1)

The Pennylvania State University

🇺🇸

University Park, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath